TRAW250117C2500
- 0.05
- 0.000.00%
Traws Pharma Newsroom
Analysts Conflicted on These Healthcare Names: Biogen (BIIB) and Traws Pharma (TRAW)
Noble Financial Maintains Traws Pharma(TRAW.US) With Buy Rating, Maintains Target Price $7
Noble Financial Maintains Traws Pharma(TRAW.US) With Buy Rating, Cuts Target Price to $7
Noble Financial Sticks to Its Buy Rating for Traws Pharma (TRAW)
Analysts Offer Insights on Healthcare Companies: Onconova Therapeutics (ONTX) and Biogen (BIIB)
Positive Financial Performance and Potential of Lead Assets Boost Onconova Therapeutics' Buy Rating: An Analysis by Joseph Pantginis
Promising Developments in Onconova Therapeutics' Drug Narazaciclib Bolster Buy Rating: An Analysis
Promising Clinical Results and Progress in Trials Lead to Buy Rating for Onconova Therapeutics
HC Wainwright & Co. Reiterates Buy on Onconova Therapeutics, Maintains $11 Price Target
Onconova Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Onconova Therapeutics, Maintains $11 Price Target
Onconova Therapeutics Analyst Ratings
H.C. Wainwright Sticks to Their Buy Rating for Onconova Therapeutics (ONTX)
Noble Financial Keeps Their Buy Rating on Onconova Therapeutics (ONTX)
Onconova Therapeutics (ONTX) Receives a Buy From H.C. Wainwright
HC Wainwright & Co. Reiterates Buy on Onconova Therapeutics, Maintains $11 Price Target
Onconova Therapeutics (ONTX) Gets a Buy From H.C. Wainwright
Onconova Therapeutics (ONTX) Gets a Buy From Noble Financial
Analysts Offer Insights on Healthcare Companies: Onconova Therapeutics (ONTX), Cara Therapeutics (CARA) and Minerva Neurosciences (NERV)
Onconova Therapeutics (ONTX) Gets a Buy From H.C. Wainwright